Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of Interleukin-2 (IL-2) Superkines for the treatment of cancer. The company's Superkine platform is designed to enhance IL-2's anti-tumor activity while minimizing its toxic effects, potentially offering a more effective and safer approach to cancer immunotherapy. Medicenna is actively pursuing clinical trials to evaluate the efficacy and safety of its lead product candidates in various cancer indications. By engineering IL-2 to selectively target and activate immune cells that fight cancer, Medicenna aims to create next-generation immunotherapies that can improve patient outcomes and address unmet medical needs in oncology. The company's research and development efforts are centered on advancing the field of immuno-oncology and developing innovative treatments that harness the power of the immune system to combat cancer.